-poster-00001.jpg)
We are witnessing the first step towards a new era in over the counter wearable technology and diabetes care with Dexcom's Stelo sensor, the first over-the-counter CGM. This device is not just a leap in technology; it's a step towards greater accessibility and equity in healthcare. The Stelo sensor, with its 15-day wear period and enhanced adhesive, is designed for those managing Type 2 diabetes without insulin. Priced at just $99 for two sensors, Stelo opens the door to advanced glucose monitoring for millions, particularly when 8.5 million Americans are living with undiagnosed diabetes.
This innovation is more than a device; it’s a symbol of progress to empowering patients with the tools they need to take control of their health. By offering real-time glucose data, Stelo enables proactive management of diabetes, potentially improving outcomes and reducing complications. It’s about meeting people where they are, providing affordable and effective solutions that fit seamlessly into their lives.
As healthcare professionals and leaders, it’s our responsibility to embrace and promote advancements like Stelo that can make a meaningful difference in the lives of those we serve. This is just the beginning—together, we can build a future where no one is left behind in the fight against diabetes.